The Adverse Effects of Anabolic Steroids on Serum Lipids

Yesalis C. Incidence of anabolic steroid use: a discussion of methodological issues. In: Yesalis C , ed. Anabolic Steroids in Sport and Exercise. Champaign, Ill: Human Kinetics Publishers, 1993: 49–69.

Buckley W Yesalis C Friedl K Anderson W Streit A Wright I. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988; 260: 3441–5.

Perry HM Wright D Littlepage BNC. Dying to be big: a review of anabolic steroid use. Br J Sports Med. 1992; 26: 259–61.

Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med. 1991; 151: 1925–33.

Cohen JC Faber WM Benade AJS Noakes TD. Altered serum lipoprotein profiles in male and female power lifters ingesting anabolic steroids. Phys Sports Med. 1986; 14: 131–6.

Costill DL Pearson DR Fink WJ. Anabolic steroid use among athletes: changes in HDL-C levels. Phys Sports Med. 1984; 12: 113–17.

Thompson PD Cullinane EM Sady SP Chenevert C Saritelli AL Sady MA Contrasting effects of testosterone and stanazolol on serum lipoprotein levels. JAMA 1989; 261: 1165–8.

Lenders JW Demacker PN Vos JA Jansen PL Hoitsma AJ Van't Laar A Deleterious effects of anabolic steroids on serum lipoprotein, blood pressure, and liver function in amateur body builders. Int J Sports Med. 1988; 9: 249–52.

Applebaum-Bowden D Haffner SM Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein cholesterol. Metabolism 1987; 36: 949–52.

Albers JJ Taggart HM Applebaum-Bowden D Haffner S Chesnut C Hazzard W Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the LP(a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta 1984; 795: 293–6.